INCAGN02390
incyte
['medsir']
m. gutierrez: incagn02390 monotherapy (tim-3 antb) is well tolerated, with linear pk in first-in-human phase 1 trial. disease control rate:17.5% (1 confirmed pr during 5,6m). incagn02390 (400 mg q2w) will be further investigated in combinations with other immunotherapies. #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM